Loading...
•
Mar 31, 2022
Eton Q1 2022 Earnings Report
Eton Pharmaceuticals reported first quarter results with revenue increase driven by ALKINDI SPRINKLE®, carglumic acid, and Rezipres®.
Key Takeaways
Eton Pharmaceuticals reported a net loss of $5.3 million for the first quarter of 2022, with product sales and royalty revenue of $2.2 million. The company is experiencing growth in ALKINDI SPRINKLE® and the launch of carglumic acid and Rezipres®.
Reported fifth straight quarter of sequential growth in product sales.
Carglumic acid product launched in late-December 2021 received a favorable reception.
ALKINDI SPRINKLE® continues to grow and reported record quarterly revenue.
Eton expects 2022 revenue of at least $25 million, including $10 million of milestone payments and $15 million of product sales and royalties.
Forward Guidance
Eton expects 2022 revenue of at least $25 million, including $10 million of milestone payments and $15 million of product sales and royalties.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...